definiens: shall be defined as all upfront, license, andtechnology access fees, product milestone payments ( whether research, preclinical ordevelopmental ), and other remuneration, however characterized ( except for direct reimbursementof fully burdened research or sales personnel expenditures at rates consistent with currentindustry standards and payments based on the level of sales, profits or other levels ofcommercialization derived from Net Sales of Licensed Products by Shire A.G. or any othercompany with whom [COMPANY] revives the ACE-031 program on substantially the same terms asthe ACE-031 Agreement ( including, without limitation, [COMPANY] ’s royalties on net sales and / orsharing of Shire ’s profits, or any other company ’s profits with whom [COMPANY] revives the ACE-031 program on substantially the same terms as the ACE-031 Agreement, with Acceleron))received by [COMPANY] under the ACE-031 Agreement or other agreement that includessubstantially the same terms as the ACE-031 Agreement